For decades, cancer immunotherapy has focused primarily on CD8+ cytotoxic T lymphocytes as the main executors of tumor cell ...

Researchers designed CAR T cells that locally release VEGF-blocking molecules, weakening tumor defenses and boosting immune ...

Researchers in upstate New York are hopeful the work they’re doing may soon lead to new therapies for more cancer ...

UCLA scientists have developed a next-generation CAR-T cell therapy that can overcome the immunosuppressive tumor microenvironment, a protective shield that tumors use to weaken immune cells, block ...

Colorectal cancer (CRC) remains one of the most prevalent malignancies and a leading cause of cancer-related mortality worldwide. Beyond tumor-intrinsic ...

CD4+ T cells, long regarded as supporting actors in cancer immunity, are emerging as central regulators of tumor control and ...

Researchers at Atrium Health Wake Forest Baptist have shown that engineered macrophages can infiltrate brain tumor sites, recognize cancer cells, and destroy them in preclinical mouse models, ...

Cbio A/S today announced that it has received regulatory clearance to begin a first-in-human Phase I/IIa clinical trial of novoleucel, the company’s next-generation T-cell therapy designed to improve ...

Researchers at Moffitt Cancer Center have identified distinct spatial tumor–immune ecosystems that predict whether patients with advanced non–small-cell lung cancer will benefit from immunotherapy.

Pancreatic cancer (PC) remains one of the most lethal malignancies, largely due to late diagnosis, intrinsic therapeutic resistance, and profound immune ...